# US 10,864,240 B2 · Pharmaceutical composition for treating skin wounds and a method of treating skin wounds using thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,864,240 B2 - Document ID: US10864240B2 - Status: Granted - Kind: B2 - Application number: 16/204,352 - Filed: 2018-11-29 - Published: 2019-05-02 - Granted: 2020-12-15 - Earliest claimed: 2017-05-23 - Applicants: Yuanqiao Fu - Inventors: Yuanqiao Fu - Web page: https://patentgrep.com/patent/US10864240B2 ## CPC - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 36/324: Boswellia, e.g. frankincense - A61K 31/047: having two or more hydroxy groups, e.g. sorbitol - A61K 31/10: Sulfides; Sulfoxides; Sulfones - A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide - A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole - A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins - A61K 36/232: Angelica - A61K 36/328: Commiphora, e.g. mecca myrrh or balm of Gilead - A61K 36/481: Astragalus (milkvetch) - A61K 36/484: Glycyrrhiza (licorice) - A61K 36/537: Salvia (sage) - A61K 36/539: Scutellaria (skullcap) - A61K 36/65: Paeoniaceae (Peony family), e.g. Chinese peony - A61K 36/71: Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal - A61K 36/744: Gardenia - A61K 36/756: Phellodendron, e.g. corktree - A61K 36/87: Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine - A61K 36/889: Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto - A61K 36/898: Orchidaceae (Orchid family) - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids - A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61K 2236/33: involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way. ## Claims ### Claim 1 A liquid-state topical pharmaceutical composition for treating skin wounds comprising: (i) glycerol, (ii) water, (iii) 1,2-propanediol, (iv) laurocapram or decyl methyl sulfoxide, (v) a pharmaceutically effective component extracted by glycerol and water from at least one ingredient selected from the group consisting of Astragali Radix, Angelicae Sinensis Radix, Salviae Miltiorrhizae Radix et Rhizoma, Paeoniae Radix Rubra, Coptidis Rhizoma, Scutellariae Radix, Phellodendri Chinensis Cortex, Gardeniae Fructus, Ampelopsis Radix, Ilex purpurea Hassk, Bletillae Rhizoma, Glycyrrhizae Radix et Rhizoma, and (vi) a pharmaceutically effective component extracted by 1,2-propanediol from at least one ingredient selected from the group consisting of Olibanum, Myrrha, Draconis Sanguis and Catechu; wherein the glycerol is present in the composition in an amount of 80% to 90% by volume with respect to a total volume of the liquid-state topical pharmaceutical composition; the water is present in the composition in an amount of 3% to 8% by volume with respect to a total volume of the liquid-state topical pharmaceutical composition; the 1,2-propanediol is present in the composition in an amount of 6% to 15% by volume with respect to a total volume of the liquid-state topical pharmaceutical composition; and the laurocapram is present in the composition in an amount of 0.2% to 2% by volume with respect to a total volume of the liquid-state topical pharmaceutical composition; or the decyl methyl sulfoxide is present in the composition in an amount of 1% to 4% by volume with respect to a total volume of the liquid-state topical pharmaceutical composition. ### Claim 2 (depends on 1) The pharmaceutical composition of claim 1, comprising one or more of the following: 1) a content of Astragali Radix in the composition is 10-30 g/L; 2) a content of Angelicae Sinensis Radix in the composition is 5-20 g/L; 3) a content of Salviae Miltiorrhizae Radix et Rhizoma in the composition is 5-20 g/L; 4) a content of Paeoniae Radix Rubra in the composition is 5-20 g/L; 5) a content of Coptidis Rhizoma in the composition is 5-20 g/L; 6) a content of Scutellariae Radix in the composition is 5-20 g/L; 7) a content of Phellodendri Chinensis Cortex in the composition is 5-20 g/L; 8) a content of Gardeniae Fructus in the composition is 5-20 g/L; 9) a content of Ampelopsis Radix in the composition is 5-20 g/L; 10) a content of Ilex purpurea Hassk in the composition is 5-20 g/L; 11) a content of Bletillae Rhizoma in the composition is 5-20 g/L; 12) a content of Glycyrrhizae Radix et Rhizoma in the composition is 5-15 g/L; 13) a content of Olibanum in the composition is 3-10 g/L; 14) a content of Myrrha in the composition is 3-10 g/L; 15) a content of Draconis Sanguis in the composition is 3-10 g/L; and 16) a content of Catechu in the composition is 3-10 g/L. ### Claim 3 (depends on 1) The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises gentamicin and chloramphenicol. ### Claim 4 (depends on 1) The composition of claim 1 wherein the skin wound comprises one selected from the group consisting of burn wound, scald wound, skin contusion wound, suture wound after incision, bedsore wound, skin infection wound, and granulation tissue wound. ### Claim 5 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Astragali Radix in the composition is 10-15 g/L. ### Claim 6 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Angelicae Sinensis Radix in the composition is 6-8 g/L. ### Claim 7 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Salviae Miltiorrhizae Radix et Rhizoma in the composition is 8-10 g/L. ### Claim 8 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Paeoniae Radix Rubra in the composition is 8-10 g/L. ### Claim 9 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Coptidis Rhizoma in the composition is 6-8 g/L. ### Claim 10 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Scutellariae Radix in the composition is 6-8 g/L. ### Claim 11 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Phellodendri Chinensis Cortex in the composition is 6-8 g/L. ### Claim 12 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Gardeniae Fructus in the composition is 6-8 g/L. ### Claim 13 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Ampelopsis Radix in the composition is 8-10 g/L. ### Claim 14 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Ilex purpurea Hassk in the composition is 8-10 g/L. ### Claim 15 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Bletillae Rhizoma in the composition is 8-10 g/L. ### Claim 16 (depends on 1) The pharmaceutical composition of claim 1, wherein the content of Glycyrrhizae Radix et Rhizoma in the composition is 8-10 g/L.